最高数目的1亿股配售股份相当于紧随配售事项完成后经配发及发行最高数目的配售股份扩大后已发行 四海股份总数的约7.46%(假设自本联合公布日期起直至配售事项完成日期，四海已发行股本概无变动， 惟配发及发行配售股份除外)。每股配售股份0.108港元的配售价相当于2025年7月31日在联交所所报的 收市价每股四海股份0.126港元折让约14.3%。 智通财经APP讯，COSMOPOL INT'L(00120)与世纪城市国际(00355)发布联合公告，于2025年7月31日， 四海与配售代理订立配售协议，据此四海委任配售代理，按尽力基准且待达成配售协议的先决条件下， 以每股配售股份0.108港元的配售价配售最多1亿股配售股份予不少于六名承配人。 假设由本联合公布日期至配售事项完成日期的间四海已发行股本概无变动(惟配发及发行配售股份除 外)，而最多1亿股配售股份已获成功配售，则世纪城市于四海的股份权益百分比将由约70.30%摊薄至约 65.06%，相当于减少约 5.24%。紧随配售事项完成后摊薄世纪城市于四海的股份权益将构成上市规则第 14.29条项下世纪城市视作出售其于四海的股份权益。 估计所得款项净额(经扣除由四海 ...

Group 1 - COSMOPOL INT'L (00120) and Century City International (00355) announced a placement agreement to issue up to 100 million shares at a price of HKD 0.108 per share, representing approximately 7.46% of the enlarged issued share capital post-placement [1] - The placement price of HKD 0.108 per share reflects a discount of about 14.3% to the closing price of HKD 0.126 on July 31, 2025 [1] - Following the placement, Century City's shareholding in COSMOPOL will be diluted from approximately 70.30% to about 65.06%, a reduction of approximately 5.24% [1] Group 2 - The estimated net proceeds from the placement, after deducting all relevant expenses, are expected to be approximately HKD 10.3 million [2] - COSMOPOL intends to use the estimated net proceeds to reduce the group's debt [2]

格隆汇8月1日丨四海国际(00120.HK)及世纪城市国际(00355.HK)联合公布，2025年7月31日，四海与配 售代理(即宝新证券)订立配售协议，据此四海委任配售代理，按尽力基准且待达成配售协议的先决条件 下，以每股配售股份港币0.108元的配售价配售最多1亿股配售股份予不少于六名承配人。 每股配售股份港币0.108元的配售价相当于最后交易日在联交所所报的收市价每股四海股份港币0.126元 折让约14.3%。最高数目的1亿股配售股份相当于(i)本联合公布日期已发行四海现有股份总数的约 8.07%；及(ii)紧随配售事项完成后经配发及发行最高数目的配售股份扩大后已发行四海股份总数的约 7.46%。配售股份将根据一般授权配发及发行。 假设配售股份获全数配售，配售事项的所得款项总额预计约为港币1080万元。估计所得款项净额(经扣 除由四海因配售事项适当产生的所有费用、成本及开支(包括四海承担配售代理的佣金及中国证监会备 案相关的开支))预计约为港币1030万元。四海拟将配售事项的估计所得款项净额用作减少四海集团的债 务。 于本联合公布日期，四海为世纪城市的非全资间接附属公司。世纪城市间接持有四海股份的约 7 ...

根据上述有效接纳及申请的结果，补偿安排所涉及的未获认购股份及不合资格股东未售股份总数将为 6226万股供股股份。 新明中国(02699)发布公告，于2025年7月8日(星期二)下午四时正(即接纳最后时限)，已接获合共8份有效 申请，涉及合共1288.49万股供股股份，相当于供股项下所提呈发售供股股份总数约17.15%。 董事会谨此宣布，于2025年7月21日(星期一)下午四时正(即配售事项结束日期)，已成功根据配售事项向 不少于6名承配人配售6226万股未获认购股份，配售价为每股1.12港元，相等于认购价。因此，概无根 据配售事项可分派予不行动股东及不合资格股东的净收益。 ...

Group 1 - Company announced a placement and subscription agreement to sell 22.561 million existing shares, representing approximately 6.87% of the total issued shares as of the announcement date [1] - The purchase price is set at a discount of about 10.12% to the closing price of HKD 77.55 per share on the last trading day before the agreement [1] - The total expected proceeds from the placement and subscription are approximately HKD 1.573 billion, with net proceeds estimated at HKD 1.553 billion [2] Group 2 - The company plans to allocate 50% of the net proceeds for global research and development of pipeline products, 40% for commercialization efforts, and 10% for general administrative expenses [2] - The board believes that the placement and subscription provide an opportunity for further fundraising, which is beneficial for the long-term development of the group [2] - The initiative aims to attract long-term international institutional shareholders, enhance shareholder base, improve trading liquidity, and provide additional funding for drug pipeline development [2]

Group 1 - The company, Qizhi Group, announced a placement agreement to issue 3 million shares at a price of HKD 106.60 per share, representing approximately 1.14% of the existing issued shares [1] - The placement price reflects a discount of about 17.04% compared to the closing price of HKD 128.50 on the last trading day and a discount of approximately 17.44% compared to the average closing price of HKD 129.12 over the last five trading days [1] - The board believes that the placement will enhance the company's liquidity and financial position, expand the shareholder base, optimize the capital structure, and support sustainable development [1] Group 2 - If all placement shares are fully subscribed, the total gross proceeds are expected to be approximately HKD 320 million, with a net amount of about HKD 314 million after deducting commissions and related costs [2] - The net proceeds are planned to be used as follows: approximately 50% for domestic and international business operations, about 10% for research and development, and around 40% for optimizing the capital structure and other general corporate purposes [2] - The expected timeline for utilizing the net proceeds is by December 31, 2030, subject to adjustments based on future developments, market conditions, and business circumstances [2]

Group 1 - The company announced a share placement agreement involving its subsidiary, Sichuan Kelun Biotech Co., Ltd., to issue 5,918,000 H shares at a price of HKD 331.8 per share [1][2] - The net proceeds from the placement are expected to be HKD 1.943 billion, which will be used for product research and development, clinical trials, registration, manufacturing, commercialization, and enhancing internal R&D capabilities [1][2] - The completion of the placement is subject to certain conditions outlined in the placement agreement, indicating uncertainty regarding the timing and completion of the transaction [1] Group 2 - If the placement is successfully completed, the total shares of Kelun Biotech will change, with the company remaining the controlling shareholder with approximately 53.41% of the shares [2] - The placement aims to meet the funding needs for the continuous development and business growth of Kelun Biotech, thereby broadening its financing channels and positively impacting its operations and long-term development [2]

Group 1 - The company, Rongchang Biopharma (09995.HK), has entered into a placement agreement with Morgan Stanley and Huatai International to issue 19 million new H-shares at a placement price of HKD 42.44, which represents a discount of approximately 9.51% compared to the closing price of HKD 46.90 on May 21 [1] - The placement shares will account for about 10.02% of the existing issued H-shares and approximately 3.49% of the total issued shares as of the announcement date [1] - Assuming no other changes in the issued share capital, the placement shares will represent about 9.11% of the enlarged issued H-shares and approximately 3.37% of the total issued shares after the placement [1] Group 2 - The total estimated proceeds from the placement are approximately HKD 806 million, with net proceeds expected to be around HKD 796 million after deducting commissions and estimated expenses [2] - The company plans to use the net proceeds for the expansion of its core product, RC18, into key indications such as myasthenia gravis, membranous nephropathy, and for general corporate purposes [2]

Group 1 - The company, Wei Long Mei Wei (09985), has entered into a placement agreement to sell 80 million shares at a price of HKD 14.72 per share, which represents a discount of approximately 7.88% compared to the last closing price of HKD 15.98 [1][2] - The placement is expected to attract at least six professional or institutional investors, with no single investor anticipated to become a major shareholder post-placement [1] - The total expected gross proceeds from the placement and subscription are approximately HKD 1.178 billion, with net proceeds estimated at around HKD 1.167 billion after deducting commissions and estimated expenses [2] Group 2 - The funds raised from the placement and subscription are intended to enhance the company's financial strength, market competitiveness, and overall capabilities, promoting long-term sustainable development [2] - The placement and subscription are expected to enrich the company's shareholder base by attracting high-quality institutional investors and further improve the liquidity of the shares [2] - The board believes that the terms of the placement and subscription agreements are fair and reasonable, aligning with the best interests of the company and its shareholders [2]